In particular, we showed that the FGFR4 expression fluctuated with the genotypes of rs351855 in blood cells, implicating a differential impact of tumor-infiltrating immune cells on CRC progression according to distinct FGFR4 activation levels among patients of different rs351855 genotypes. The gene discussed is FGFR4; the disease is neoplasm.